Phase III results shed light on combination Crohn's treatment
This article was originally published in Scrip
Executive Summary
Follow-up Phase III trial results suggest that combination therapy with the anti-TNFα drug Remicade (infliximab) and the immunomodulator azathioprine helps to maintain steroid-free remission in patients with Crohn's disease.